G2

G2GBIO, Inc.

Develops long-acting injectable therapies for chronic diseases and cancer.

456160 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
충청북도 청주시 흥덕구 오송읍 의료단지길 21, 청주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

G2GBIO, Inc., founded in 2017, is a clinical-stage biotechnology company specializing in drug delivery systems (DDS) for long-acting injectables (LAI). The company develops advanced therapeutics using its proprietary InnoLAMP™ (Innovative Long-Acting MicroParticle) platform technology. This platform enables the creation of sustained-release microparticle formulations designed to improve medication convenience and patient adherence for chronic diseases. G2GBIO's development pipeline targets a range of therapeutic areas, including Alzheimer's disease, Type 2 diabetes, schizophrenia, and post-operative pain. A secondary platform, InteLAMP™, focuses on oncology treatments. The company supports its development with in-house GMP-certified research and pilot-scale production facilities.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for G2GBIO, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-19 00:00
Share Issue/Capital Change
주식매수선택권행사
Korean 39.0 KB
2025-09-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 380.4 KB
2025-09-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-09-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-09-08 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 859.0 KB
2025-08-22 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2025-08-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 433.6 KB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB

Automate Your Workflow. Get a real-time feed of all G2GBIO, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for G2GBIO, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MEDICOX Co., Ltd. Logo
Developing new drugs and building a distribution platform for healthcare solutions.
South Korea 054180
Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan 2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea 078160
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea 236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea 086900
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan 2207
Merck KGaA Logo
A science & tech firm in healthcare, life science, and electronics, advancing human progress.
United States of America 6MK

Talk to a Data Expert

Have a question? We'll get back to you promptly.